Publications by authors named "Floyd Fox"

Claim this Profile
M
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.
David S Hong, Olivier Rixe, Vi K Chiu, Patrick M Forde, Tomislav Dragovich, Floyd E Fox

Clin Cancer Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, Solmaz Sahebjam, Mario Sznol, Floyd E Fox

Clin Cancer Res· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
Patricia M LoRusso, Smitha Krishnamurthi, Hagop Youssoufian, Nancy Hall, Floyd Fox

Invest New Drugs· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.
Eric K Rowinsky, Jonathan D Schwartz, Naseem Zojwalla, Hagop Youssoufian, Floyd Fox

Curr Drug Targets· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Bart Kuenen, Petronella O Witteveen, Rita Ruijter, Giuseppe Giaccone, Aruna Dontabhaktuni, Floyd Fox

Clin Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Jennifer L Spratlin, Roger B Cohen, Matthew Eadens, Lia Gore, D Ross Camidge, Floyd Fox

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.
Dale L Ludwig, Larry Witte, Daniel J Hicklin, Marie Prewett, Rajiv Bassi, Floyd Fox

Hum Antibodies· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
James A Posey, Thian C Ng, Baolian Yang, M B Khazaeli, Mark D Carpenter, Floyd Fox

Clin Cancer Res· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diminished expression of the type II receptor for TGFbeta (TGFbetaRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeric base stretches.
Qian Zhang, Renold J Capocasale, Floyd E Fox, Vahe Bedian, Eric C Vonderheid

Arch Immunol Ther Exp (Warsz)· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation.
Xiao-yu R Song, Floyd Fox, Mary Ann Gallo, Amy Rosenberg, Robert Jordan

J Infect Dis· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis